Victoria Cardona

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8233347/publications.pdf

Version: 2024-02-01

144 papers 9,440 citations

41344 49 h-index 93 g-index

161 all docs

161 docs citations

times ranked

161

7171 citing authors

#	Article	IF	CITATIONS
1	EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1008-1025.	5.7	979
2	Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1026-1045.	5.7	809
3	World Allergy Organization Anaphylaxis Guidance 2020. World Allergy Organization Journal, 2020, 13, 100472.	3.5	461
4	The epidemiology of food allergy in Europe: a systematic review and metaâ€analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 62-75.	5.7	407
5	International consensus on (ICON) anaphylaxis. World Allergy Organization Journal, 2014, 7, 9.	3.5	360
6	The epidemiology of anaphylaxis in Europe: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1353-1361.	5.7	306
7	First European data from the network of severe allergic reactions (<scp>NORA</scp>). Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1397-1404.	5.7	247
8	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organization Journal, 2020, 13, 100080.	3.5	245
9	EAACI guidelines: Anaphylaxis (2021 update). Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 357-377.	5.7	193
10	Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1322-1330.	5.7	176
11	Primary prevention of food allergy in children and adults: systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 581-589.	5.7	168
12	Usefulness and Limitations of Sequential Serum Tryptase for the Diagnosis of Anaphylaxis in 102 Patients. International Archives of Allergy and Immunology, 2013, 160, 192-199.	2.1	144
13	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
14	Time to revisit the definition and clinical criteria for anaphylaxis?. World Allergy Organization Journal, 2019, 12, 100066.	3.5	137
15	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A <scp>EUFOREA</scp> â€ <scp>ARIA</scp> â€ <scp>EPOS</scp> â€ <scp>AIRWAYS ICP</scp> statement. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1297-1305.	5.7	130
16	Research needs in allergy: an EAACI position paper, in collaboration with EFA. Clinical and Translational Allergy, 2012, 2, 21.	3.2	127
17	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clinical and Translational Allergy, 2016, 6, 47.	3.2	121
18	COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organization Journal, 2021, 14, 100517.	3.5	121

#	Article	IF	Citations
19	Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions. Journal of Allergy and Clinical Immunology, 2015, 135, 1031-1043.e6.	2.9	120
20	Foodâ€induced fatal anaphylaxis: From epidemiological data to general prevention strategies. Clinical and Experimental Allergy, 2018, 48, 1584-1593.	2.9	120
21	Management of anaphylaxis: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 168-175.	5.7	109
22	Coâ€factorâ€enhanced food allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 1316-1318.	5.7	104
23	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. Clinical and Translational Allergy, 2018, 8, 45.	3.2	104
24	Vaccination and allergy: <scp>EAACI</scp> position paper, practical aspects. Pediatric Allergy and Immunology, 2017, 28, 628-640.	2.6	103
25	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. Journal of Allergy and Clinical Immunology, 2019, 143, 864-879.	2.9	103
26	Particularities of allergy in the Tropics. World Allergy Organization Journal, 2016, 9, 20.	3.5	101
27	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	3.2	97
28	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	3.2	97
29	The role of mobile health technologies in allergy care: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 259-272.	5.7	95
30	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
31	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	3.2	81
32	The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1792-1800.	5.7	79
33	COVIDâ€19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
34	Perspectives in allergen immunotherapy: 2017 and beyond. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 5-23.	5.7	76
35	A WAO â€" ARIA â€" GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organization Journal, 2020, 13, 100091.	3.5	76
36	Validation of the <scp>MASK</scp> â€rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. Clinical and Experimental Allergy, 2017, 47, 1526-1533.	2.9	75

#	Article	IF	CITATIONS
37	Acute and long-term management of food allergy: systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 159-167.	5.7	74
38	Adherence to treatment in allergic rhinitis using mobile technology. The <scp>MASK</scp> Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	2.9	73
39	Component resolved diagnosis: when should it be used?. Clinical and Translational Allergy, 2014, 4, 28.	3.2	70
40	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergologie Select, 2019, 3, 22-50.	3.1	70
41	The Mast Cell, Contact, and Coagulation System Connection in Anaphylaxis. Frontiers in Immunology, 2017, 8, 846.	4.8	60
42	Critical view of anaphylaxis epidemiology: open questions and new perspectives. Allergy, Asthma and Clinical Immunology, 2018, 14, 12.	2.0	59
43	Allergic diseases in the elderly. Clinical and Translational Allergy, 2011, 1, 11.	3.2	57
44	ARIAâ€EAACI statement on asthma and COVIDâ€19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
45	One hundred years of allergen immunotherapy <scp>E</scp> uropean <scp>A</scp> cademy of <scp>A</scp> llergy and <scp>C</scp> linical <scp>I</scp> mmunology celebration: review of unanswered questions. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 462-476.	5.7	56
46	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp> â€ <scp>ARIA</scp>) â€ <scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project). Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 77-92.	5.7	54
47	Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research project. Health and Quality of Life Outcomes, 2012, 10, 82.	2.4	52
48	Clinical trials in allergen immunotherapy: current concepts and future needs. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1775-1783.	5.7	52
49	<scp>ARIA</scp> pharmacy 2018 "Allergic rhinitis care pathways for community pharmacy― Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1219-1236.	5.7	52
50	Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA. Journal of Nutrition, Health and Aging, 2017, 21, 92-104.	3.3	47
51	Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases–11. Journal of Allergy and Clinical Immunology, 2019, 144, 627-633.	2.9	46
52	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
53	Analysis of mite allergic patients in a diverse territory by improved diagnostic tools. Clinical and Experimental Allergy, 2012, 42, 1129-1138.	2.9	45
54	Challenges in the implementation of the <scp>EAACI AIT</scp> guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 827-836.	5.7	44

#	Article	IF	CITATIONS
55	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2511-2523.	3.8	44
56	Diagnostic test allergens used for <i>inÂvivo</i> diagnosis of allergic diseases are at risk: a European Perspective. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1329-1331.	5.7	43
57	Immunotherapy in allergic rhinitis and lower airway outcomes. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 35-42.	5.7	40
58	Phenotype and risk factors of venom-induced anaphylaxis: AÂcase-control study of the European Anaphylaxis Registry. Journal of Allergy and Clinical Immunology, 2021, 147, 653-662.e9.	2.9	40
59	Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1493-1506.	5.7	40
60	Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers. Medicina ClÃnica, 2022, 159, 116-123.	0.6	40
61	Peanutâ€induced anaphylaxis in children and adolescents: Data from the European Anaphylaxis Registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1517-1527.	5.7	39
62	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRAIL report. Clinical and Translational Allergy, 2017, 7, 37.	3.2	36
63	Safety of Adrenaline Use in Anaphylaxis: A Multicentre Register. International Archives of Allergy and Immunology, 2017, 173, 171-177.	2.1	35
64	Treatment of allergic rhinitis during and outside the pollen season using mobile technology. A MASK study. Clinical and Translational Allergy, 2020, 10, 62.	3.2	34
65	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. World Allergy Organization Journal, 2018, 11, 15.	3.5	33
66	Applying prevention concepts to anaphylaxis: A call for worldwide availability of adrenaline autoâ€injectors. Clinical and Experimental Allergy, 2017, 47, 1108-1114.	2.9	32
67	Correlation between work impairment, scores of rhinitis severity and asthma using the MASKâ€air∢sup>®∢/sup> App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	5.7	32
68	Development and validation of combined symptomâ€medication scores for allergic rhinitis*. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2147-2162.	5.7	32
69	Differentiation of COVIDâ€19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€EAACIâ€GA ² LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
70	Update on latex allergy: New insights into an old problem. World Allergy Organization Journal, 2021, 14, 100569.	3.5	31
71	Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASKâ€air®. Clinical and Translational Allergy, 2021, 11, e12062.	3.2	31
72	Development and Validation of a New Spanish Instrument to Measure Health-Related Quality of Life in Patients with Allergic Rhinitis: The ESPRINT Questionnaire. Value in Health, 2007, 10, 466-477.	0.3	30

#	Article	IF	CITATIONS
73	Oestrogenâ€dependent hereditary angioâ€oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 735-741.	5.7	29
74	Biomarkers of anaphylaxis, beyond tryptase. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 329-336.	2.3	28
75	Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2844-2852.e5.	3.8	28
76	Allergy immunotherapy across the life cycle to promote active and healthy ageing: from research to policies. Clinical and Translational Allergy, 2016, 6, 41.	3.2	24
77	In-flight allergic emergencies. World Allergy Organization Journal, 2017, 10, 15.	3.5	24
78	Phenotypes, endotypes and biomarkers in anaphylaxis: current insights. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 370-376.	2.3	24
79	ARIAâ€EAACI care pathways for allergen immunotherapy in respiratory allergy. Clinical and Translational Allergy, 2021, 11, e12014.	3.2	24
80	Inâ€vivo diagnostic test allergens in Europe: A call to action and proposal for recovery plan—An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2161-2169.	5 . 7	23
81	Allergology in <scp>E</scp> urope, the blueprint. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1211-1218.	5.7	22
82	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. Allergo Journal International, 2019, 28, 255-276.	2.0	22
83	Association of thromboxane A1 synthase (TBXAS1) gene polymorphism with acute urticaria induced by nonsteroidal anti-inflammatory drugs. Journal of Allergy and Clinical Immunology, 2013, 132, 989-991.	2.9	21
84	The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease. International Archives of Allergy and Immunology, 2017, 174, 35-44.	2.1	21
85	Validation of the first treatment-specific questionnaire for the assessment of patient satisfaction with allergen-specific immunotherapy in allergic patients: The ESPIA questionnaire. Journal of Allergy and Clinical Immunology, 2013, 131, 1539-1546.e2.	2.9	20
86	B-lymphocytes and co-stimulatory molecules in Mycobacterium tuberculosis infection. International Journal of Tuberculosis and Lung Disease, 2004, 8, 98-105.	1.2	20
87	Component-resolved diagnosis in anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2016, 16, 244-249.	2.3	17
88	Current practice of allergy diagnosis and the potential impact of regulation in Europe. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 323-327.	5 . 7	17
89	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASKâ€air [®] realâ€world data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2699-2711.	5.7	17
90	Welcome to <i>Clinical and Translational Allergy</i> i>. Clinical and Translational Allergy, 2011, 1, 1.	3.2	16

#	Article	IF	CITATIONS
91	Management of anaphylaxis due to COVIDâ€19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	5 . 7	16
92	Allergenicity and cross-reactivity of Senecio pollen: identification of novel allergens using the immunoproteomics approach. Clinical and Experimental Allergy, 2008, 38, 1048-1060.	2.9	15
93	New trends in anaphylaxis. Allergo Journal International, 2017, 26, 295-300.	2.0	15
94	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 2). Journal of Thoracic Disease, 2019, 11, 4072-4084.	1.4	15
95	Biologics and anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2019, 19, 439-446.	2.3	15
96	Current Trends in Prevalence and Mortality of Anaphylaxis. Current Treatment Options in Allergy, 2016, 3, 205-211.	2.2	14
97	One-Dilution Rapid Desensitization Protocol toÂChemotherapeutic and Biological Agents: AÂFive-Year Experience. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4045-4054.	3.8	14
98	IMMEDIATE-TYPE HYPERSENSITIVITY REACTION TO LEVOTHYROXINE AND DESENSITIZATION. Annals of Allergy, Asthma and Immunology, 2008, 100, 513-514.	1.0	13
99	Lettuce Allergy Is a Lipid Transfer Syndrome-Related Food Allergy With a High Risk of Severe Reactions. Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 98-103.	1.3	13
100	Fighting allergies beyond symptoms: The European Declaration on Immunotherapy. European Journal of Immunology, 2011, 41, 2802-2804.	2.9	12
101	Foodâ€dependent NSAIDâ€induced hypersensitivity (FDNIH) reactions: Unraveling the clinical features and risk factors. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1480-1492.	5.7	12
102	Spirometric Maneuvers and Inhaled Salbutamol Do Not Affect Exhaled Nitric Oxide Measurements among Patients with Allergic Asthma. Respiration, 2012, 83, 239-244.	2.6	11
103	lgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis. International Archives of Allergy and Immunology, 2014, 165, 244-246.	2.1	11
104	Next-generation care pathways for allergic rhinitis and asthma multimorbidity: a model for multimorbid non-communicable diseases—Meeting Report (Part 1). Journal of Thoracic Disease, 2019, 11, 3633-3642.	1.4	11
105	A Proposal from the Montpellier World Health Organization Collaborating Centre for Better Management and Prevention of Anaphylaxis. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 676-683.e1.	3.8	11
106	Assessment of the Control of Allergic Rhinitis and Asthma Test (CARAT) using MASK-air. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 343-345.e2.	3.8	11
107	Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 901-910.	5.7	10
108	Component-Resolved Diagnosis of Dog Allergy. Journal of Investigational Allergology and Clinical Immunology, 2017, 27, 185-187.	1.3	9

#	Article	IF	CITATIONS
109	Allergen immunotherapy in MASKâ€air users in realâ€life: Results of a Bayesian mixedâ€effects model. Clinical and Translational Allergy, 2022, 12, e12128.	3.2	9
110	Heterogeneity of the pharmacologic treatment of allergic rhinitis in Europe based on MIDAS and OTCims platforms. Clinical and Experimental Allergy, 2021, 51, 1033-1045.	2.9	8
111	Comparison of rhinitis treatments using <scp>MASK</scp> â€air® data and considering the minimal important difference. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3002-3014.	5.7	8
112	Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy. Immunotherapy, 2013, 5, 1295-1303.	2.0	7
113	Safe and Time-Saving Desensitization Protocol to Intravenous Etoposide. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 793-794.	3.8	7
114	Drug-induced anaphylaxisâ€"elicitors, mechanisms and diagnosis. Allergo Journal International, 2019, 28, 327-329.	2.0	7
115	Molecular diagnosis usefulness for idiopathic anaphylaxis. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 248-252.	2.3	7
116	Generalised delayed desquamative exanthema after intradermal testing with betalactam antibiotics. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 702-703.	5.7	6
117	Digital technology for anaphylaxis management impact on patient behaviour: A randomized clinical trial. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1507-1516.	5.7	6
118	Foodâ€induced anaphylaxis morbidity: Emergency department and hospitalization data support preventive strategies. Pediatric Allergy and Immunology, 2021, 32, 1730-1742.	2.6	6
119	Relevance of Allergenic Sensitization to Cynodon dactylon and Phragmites communis: Cross-reactivity With Pooideae Grasses. Journal of Investigational Allergology and Clinical Immunology, 2016, 26, 295-303.	1.3	5
120	Delayed drug hypersensitivity to bortezomib: Desensitization and tolerance to its analogue carfilzomib. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1384-1386.	5.7	5
121	Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview. Molecular Diagnosis and Therapy, 2021, 25, 563-576.	3.8	5
122	Acquired angioedema associated with hereditary angioedema due to C1 inhibitor deficiency. Journal of Investigational Allergology and Clinical Immunology, 2008, 18, 126-30.	1.3	5
123	Definition, Epidemiology, and Pathogenesis. Current Treatment Options in Allergy, 2015, 2, 207-217.	2.2	4
124	Anaphylactic shock to meropenem with ertapenem tolerance: A case report. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2057-2058.	3.8	4
125	Knowledge of anaphylaxis among ibero-American physicians: results of the Ibero-American Online Survey for Physicians on the management and treatment of anaphylaxis (IOSPTA) -Latin American society of Allergy, Asthma & Immunology (LASAAI). Journal of Investigational Allergology and Clinical Immunology, 2013, 23, 441-3.	1.3	4
126	Development of a questionnaire to assess patient satisfaction with allergen-specific immunotherapy in adults: item generation, item reduction, and preliminary validation. Patient Preference and Adherence, 2011, 5, 239.	1.8	3

#	Article	IF	CITATIONS
127	Enfermedad de riesgo vital de origen respiratorio o alérgico en el deporte. Apunts Medicine De L'Esport, 2015, 50, 35-42.	0.5	3
128	Characteristics, quality of life and control of respiratory allergic diseases caused by house dust mites (HDMs) in Spain: a cross-sectional study. Clinical and Translational Allergy, 2019, 9, 39.	3.2	3
129	Cypress Pollen Allergy in a Mediterranean Area. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 67-69.	1.3	3
130	Kounis Syndrome. Current Treatment Options in Allergy, 2019, 6, 289-296.	2.2	2
131	ARIA-Versorgungspfade fÃ⅓r die Allergenimmuntherapie 2019. Allergologie, 2019, 42, 404-425.	0.1	2
132	Anafilaxia, el riesgo del infradiagnóstico. Semergen, 2008, 34, 17-19.	0.5	1
133	Knowledge of the Ibero-American Physicians On Anaphylaxis: Results of the Ibero-American Online Survey for Physicians On the Management and Treatment of Anaphylaxis (IOSPTA) - Latin American Society of Allergy, Asthma & Dy Hamunology (LASAAI). Journal of Allergy and Clinical Immunology, 2013. 131. AB220.	2.9	1
134	Fatal Anaphylactic Shock Induced by Intravenous Gelatin Colloid: A Postmortem Allergological Work-up. Journal of Investigational Allergology and Clinical Immunology, 2020, 30, 143-145.	1.3	1
135	Anaphylaxis viewed by experts: unmet needs. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 435-441.	2.3	1
136	Frozen fruit skin prick test for the diagnosis of fruit allergy. Asian Pacific Journal of Allergy and Immunology, 2010, 28, 275-8.	0.4	1
137	Molecular diagnosis contribution for personalized medicine. Current Opinion in Allergy and Clinical Immunology, 2022, Publish Ahead of Print, .	2.3	1
138	SAFETY OF EBASTINE. Annals of Allergy, Asthma and Immunology, 2005, 94, 407.	1.0	0
139	Anaphylactic reaction due to razor shell. Clinical and Translational Allergy, 2011, 1, .	3.2	O
140	Relevance of food allergy in the assessment of NSAIDâ€involved reactions. Clinical and Translational Allergy, 2015, 5, O22.	3.2	0
141	Specific molecular allergic sensitisation patterns in pediatric polysensitised patients. World Allergy Organization Journal, 2015, 8, A152.	3.5	0
142	The Use of Molecular Allergy Diagnosis in Anaphylaxis: a Literature Review. Current Treatment Options in Allergy, 2019, 6, 142-155.	2.2	0
143	Clinical Features, Inducers and Treatment of Anaphylaxis in Latin America and Spain. Journal of Allergy and Clinical Immunology, 2020, 145, AB77.	2.9	0
144	ARIA-Leitlinie 2019: Behandlung der allergischen Rhinitis im deutschen Gesundheitssystem. Allergologie, 2020, 43, 43-72.	0.1	0